Areas of disease expected as possible indications for “Regeneration-Inducing Medicine™”

Because “Regeneration-Inducing Medicine™” does not act directly on the affected part of the disease, but instead acts on stem cells present in areas such as the bone marrow or blood, it may overcome many issues associated with conventional regenerative medicine/cell therapy, and can target treatment for diseases that have been difficult to treat with conventional therapies. If our “Regeneration-Inducing Medicine™” is put into practice, it is expected to develop a broad range of clinical applications.

Overview of development pipeline

Our research and development pipeline is show below, together with the current state of progress. The pipeline is divided into the following five projects . The main target markets for each pipeline are Japan, the US and Europe.

In the case of epidermolysis bullosa, the number of target patients with epidermolysis bullosa dystrophica, is around 400 in Japan, and therefore it is not feasible to plan a large-scale phase 3 study. In addition, epidermolysis bullosa dystrophica is a rare intractable disease, and there is currently no effective therapy. Accordingly, we expect to apply for a marketing approval for the drug based on the results of the additional phase 2 study.